RNA, U2 small nuclear 64, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-64P profile across patient tissues and cancer cell-line models. RNU2-64P expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RNU2-64P is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, RNU2-64P RNA expression shows 8,042 significant gene co-expression associations, with the highest sampling consensus in LUAD. Together, these results highlight LIHC, THCA, and LUAD as cancer lineages where RNU2-64P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-64P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-64P survival associations across molecular data types. RNU2-64P RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-64P RNA expression–survival associations across cancer types. High RNU2-64P expression shows unfavorable associations in LIHC, PAAD, BLCA, SKCM, STAD and OV. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RNU2-64P RNA expression.
This table summarizes RNU2-64P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-64P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-64P shows lower tumor expression in THCA and higher tumor expression in STAD. The THCA box plot shows higher RNU2-64P RNA expression in normal versus tumor tissue (log2 FC = −0.062, t-test p = .033).
This table shows molecular features associated with RNU2-64P in patient tissues and cancer cell lines. In patient samples, RNU2-64P shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
